<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genet Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Med</journal-id>
<journal-title-group>
<journal-title>Genetics in Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1098-3600</issn>
<issn pub-type="epub">1530-0366</issn>
<publisher>
<publisher-name>Nature Publishing Group US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30190612</article-id>
<article-id pub-id-type="pmc">6405313</article-id>
<article-id pub-id-type="publisher-id">266</article-id>
<article-id pub-id-type="doi">10.1038/s41436-018-0266-3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rare variants in the genetic background modulate cognitive and developmental phenotypes in individuals carrying disease-associated variants</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pizzo</surname>
<given-names>Lucilla</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jensen</surname>
<given-names>Matthew</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Polyak</surname>
<given-names>Andrew</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenfeld</surname>
<given-names>Jill A.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mannik</surname>
<given-names>Katrin</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krishnan</surname>
<given-names>Arjun</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff6">6</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCready</surname>
<given-names>Elizabeth</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pichon</surname>
<given-names>Olivier</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Le Caignec</surname>
<given-names>Cedric</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Van Dijck</surname>
<given-names>Anke</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pope</surname>
<given-names>Kate</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Voorhoeve</surname>
<given-names>Els</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="Aff13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yoon</surname>
<given-names>Jieun</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stankiewicz</surname>
<given-names>Paweł</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheung</surname>
<given-names>Sau Wai</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pazuchanics</surname>
<given-names>Damian</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huber</surname>
<given-names>Emily</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Vijay</given-names>
</name>
<degrees>MAS</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kember</surname>
<given-names>Rachel L.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mari</surname>
<given-names>Francesca</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="Aff15">15</xref>
<xref ref-type="aff" rid="Aff16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Curró</surname>
<given-names>Aurora</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff15">15</xref>
<xref ref-type="aff" rid="Aff16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castiglia</surname>
<given-names>Lucia</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="Aff17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Galesi</surname>
<given-names>Ornella</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="Aff17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Avola</surname>
<given-names>Emanuela</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mattina</surname>
<given-names>Teresa</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff18">18</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fichera</surname>
<given-names>Marco</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff17">17</xref>
<xref ref-type="aff" rid="Aff18">18</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mandarà</surname>
<given-names>Luana</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff19">19</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vincent</surname>
<given-names>Marie</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nizon</surname>
<given-names>Mathilde</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mercier</surname>
<given-names>Sandra</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bénéteau</surname>
<given-names>Claire</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blesson</surname>
<given-names>Sophie</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff20">20</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martin-Coignard</surname>
<given-names>Dominique</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff21">21</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mosca-Boidron</surname>
<given-names>Anne-Laure</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff22">22</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Caberg</surname>
<given-names>Jean-Hubert</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff23">23</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bucan</surname>
<given-names>Maja</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zeesman</surname>
<given-names>Susan</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="Aff24">24</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nowaczyk</surname>
<given-names>Małgorzata J. M.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff24">24</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lefebvre</surname>
<given-names>Mathilde</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff25">25</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faivre</surname>
<given-names>Laurence</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff26">26</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Callier</surname>
<given-names>Patrick</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff22">22</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Skinner</surname>
<given-names>Cindy</given-names>
</name>
<degrees>RN</degrees>
<xref ref-type="aff" rid="Aff27">27</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Keren</surname>
<given-names>Boris</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff28">28</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perrine</surname>
<given-names>Charles</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff28">28</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prontera</surname>
<given-names>Paolo</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff29">29</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marle</surname>
<given-names>Nathalie</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff22">22</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Renieri</surname>
<given-names>Alessandra</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="Aff15">15</xref>
<xref ref-type="aff" rid="Aff16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reymond</surname>
<given-names>Alexandre</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kooy</surname>
<given-names>R. Frank</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Isidor</surname>
<given-names>Bertrand</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schwartz</surname>
<given-names>Charles</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff27">27</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Romano</surname>
<given-names>Corrado</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sistermans</surname>
<given-names>Erik</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Amor</surname>
<given-names>David J.</given-names>
</name>
<degrees>MBBS, PhD</degrees>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Andrieux</surname>
<given-names>Joris</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff30">30</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Girirajan</surname>
<given-names>Santhosh</given-names>
</name>
<degrees>MBBS, PhD</degrees>
<address>
<email>sxg47@psu.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2097 4281</institution-id><institution-id institution-id-type="GRID">grid.29857.31</institution-id><institution>Department of Biochemistry and Molecular Biology, </institution><institution>The Pennsylvania State University, </institution></institution-wrap>University Park, PA USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412748.c</institution-id><institution>St. George’s University School of Medicine, </institution></institution-wrap>True Blue Point, Grenada </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution>Department of Molecular &amp; Human Genetics, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2165 4204</institution-id><institution-id institution-id-type="GRID">grid.9851.5</institution-id><institution>Center for Integrative Genomics, </institution><institution>University of Lausanne, </institution></institution-wrap>Lausanne, Switzerland </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0943 7661</institution-id><institution-id institution-id-type="GRID">grid.10939.32</institution-id><institution>Estonian Genome Center, </institution><institution>Institute of Genomics, University of Tartu, </institution></institution-wrap>Tartu, Estonia </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 1785</institution-id><institution-id institution-id-type="GRID">grid.17088.36</institution-id><institution>Department of Computational Mathematics, </institution><institution>Science and Engineering, Michigan State University, </institution></institution-wrap>East Lansing, MI USA </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 1785</institution-id><institution-id institution-id-type="GRID">grid.17088.36</institution-id><institution>Department of Biochemistry and Molecular Biology, </institution><institution>Michigan State University, </institution></institution-wrap>East Lansing, MI USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>Department of Pathology and Molecular Medicine, </institution><institution>McMaster University, Hamilton, </institution></institution-wrap>Ontario, Canada </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0472 0371</institution-id><institution-id institution-id-type="GRID">grid.277151.7</institution-id><institution>CHU Nantes, Medical genetics department, </institution></institution-wrap>Nantes, France </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.457374.6</institution-id><institution>INSERM, UMR1238, Bone sarcoma and remodeling of calcified tissue, </institution></institution-wrap>Nantes, France </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3418</institution-id><institution-id institution-id-type="GRID">grid.411414.5</institution-id><institution>Department of Medical Genetics, </institution><institution>University and University Hospital Antwerp, </institution></institution-wrap>Antwerp, Belgium </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9442 535X</institution-id><institution-id institution-id-type="GRID">grid.1058.c</institution-id><institution>Department of Paediatrics, Royal Children’s Hospital, </institution><institution>Murdoch Children’s Research Institute and University of Melbourne, </institution></institution-wrap>Melbourne, Australia </aff>
<aff id="Aff13"><label>13</label>Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution>Department of Genetics, Perelman School of Medicine, </institution><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA USA </aff>
<aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 4641</institution-id><institution-id institution-id-type="GRID">grid.9024.f</institution-id><institution>Medical Genetics, University of Siena, </institution></institution-wrap>Siena, Italy </aff>
<aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1759 0844</institution-id><institution-id institution-id-type="GRID">grid.411477.0</institution-id><institution>Medical Genetics, Azienda Ospedaliera Universitaria Senese, </institution></institution-wrap>Siena, Italy </aff>
<aff id="Aff17"><label>17</label>Oasi Research Institute–IRCCS, Troina, Italy </aff>
<aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1969</institution-id><institution-id institution-id-type="GRID">grid.8158.4</institution-id><institution>Medical Genetics, University of Catania School of Medicine, </institution></institution-wrap>Catania, Italy </aff>
<aff id="Aff19"><label>19</label>Medical Genetics, ASP Ragusa, Ragusa, Italy </aff>
<aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1765 1563</institution-id><institution-id institution-id-type="GRID">grid.411777.3</institution-id><institution>Department of genetics, </institution><institution>Bretonneau university hospital, </institution></institution-wrap>Tours, France </aff>
<aff id="Aff21"><label>21</label>Service de Cytogenetique, CHU de Le Mans, Le Mans, France </aff>
<aff id="Aff22"><label>22</label>Laboratoire de Genetique Chromosomique et Moleculaire, CHU Dijon, France </aff>
<aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8607 6858</institution-id><institution-id institution-id-type="GRID">grid.411374.4</institution-id><institution>Centre Hospitalier Universitaire de Liège. Domaine Universitaire du Sart Tilman, </institution></institution-wrap>Liège, Belgium </aff>
<aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>McMaster University, Hamilton, </institution></institution-wrap>Ontario, Canada </aff>
<aff id="Aff25"><label>25</label>Centre de Genetique. Hopital d’Enfants Dijon, Dijon, France </aff>
<aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.31151.37</institution-id><institution>Center for Rare Diseases and Reference Developmental Anomalies and Malformation Syndromes, CHU Dijon, </institution></institution-wrap>Dijon, France </aff>
<aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8571 0933</institution-id><institution-id institution-id-type="GRID">grid.418307.9</institution-id><institution>Greenwood Genetic Center, </institution></institution-wrap>Greenwood, SC USA </aff>
<aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>Hopital La Pitie Salpetriere, </institution></institution-wrap>Paris, France </aff>
<aff id="Aff29"><label>29</label>Medical Genetics Unit, Hospital “Santa Maria della Misericordia”, Perugia, Italy </aff>
<aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0593 6676</institution-id><institution-id institution-id-type="GRID">grid.414184.c</institution-id><institution>Institut de Genetique Medicale, Hopital Jeanne de Flandre, CHRU de Lille, </institution></institution-wrap>Lille, France </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>7</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>7</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>816</fpage>
<lpage>825</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>4</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Purpose</title>
<p id="Par1">To assess the contribution of rare variants in the genetic background toward variability of neurodevelopmental phenotypes in individuals with rare copy-number variants (CNVs) and gene-disruptive variants.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">We analyzed quantitative clinical information, exome sequencing, and microarray data from 757 probands and 233 parents and siblings who carry disease-associated variants.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">The number of rare likely deleterious variants in functionally intolerant genes (“other hits”) correlated with expression of neurodevelopmental phenotypes in probands with 16p12.1 deletion (<italic>n</italic>=23, <italic>p</italic>=0.004) and in autism probands carrying gene-disruptive variants (<italic>n</italic>=184, <italic>p</italic>=0.03) compared with their carrier family members. Probands with 16p12.1 deletion and a strong family history presented more severe clinical features (<italic>p</italic>=0.04) and higher burden of other hits compared with those with mild/no family history (<italic>p</italic>=0.001). The number of other hits also correlated with severity of cognitive impairment in probands carrying pathogenic CNVs (<italic>n</italic>=53) or de novo pathogenic variants in disease genes (<italic>n</italic>=290), and negatively correlated with head size among 80 probands with 16p11.2 deletion. These co-occurring hits involved known disease-associated genes such as <italic>SETD5</italic>, <italic>AUTS2</italic>, and <italic>NRXN1</italic>, and were enriched for cellular and developmental processes.</p>
</sec>
<sec>
<title>Conclusion</title>
<p id="Par4">Accurate genetic diagnosis of complex disorders will require complete evaluation of the genetic background even after a candidate disease-associated variant is identified.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>CNV</kwd>
<kwd>autism</kwd>
<kwd>16p11.2 deletion</kwd>
<kwd>phenotypic variability</kwd>
<kwd>modifier</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© American College of Medical Genetics and Genomics 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p id="Par5">Significant advances in high-throughput genomic sequencing technologies have helped to identify hundreds of genes as risk factors for neurodevelopmental and neuropsychiatric disorders, including autism, intellectual disability, schizophrenia, and epilepsy. For example, in 2002, only 2–3% of autism cases were explained by genetic factors, whereas current studies suggest that rare disruptive variants, including copy-number variants (CNVs) and single-nucleotide variants (SNVs), account for 10–30% of autism cases.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Despite initial claims of association with a specific disorder or syndrome, several of these pathogenic variants show incomplete penetrance and variable expressivity.<sup><xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref></sup> For example, the 16p11.2 BP4-BP5 deletion (OMIM 611913) was first described in children with autism, but further studies on other clinical and population cohorts demonstrated that this deletion is also associated with intellectual disability and developmental delay (ID/DD), obesity, epilepsy, cardiac disease, and scoliosis, and only about 24% of cases manifest an autism phenotype.<sup><xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref></sup> Phenotypic variability is not restricted to multigenic CNVs but has also been reported for single genes with pathogenic variants, including <italic>DISC1</italic>, <italic>PTEN</italic>, <italic>SCN1A</italic>, <italic>CHD2</italic>, <italic>NRXN1</italic>, <italic>FOXP2,</italic> and <italic>GRIN2B</italic>.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> While some of these effects could be due to allelic heterogeneity, phenotypic variability among carriers of the same molecular lesion suggests a strong role for variants in the genetic background.<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup> For example, in a large family described by St. Clair and colleagues,<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> carriers of a balanced translocation disrupting <italic>DISC1</italic> manifested a wide range of neuropsychiatric features, including schizophrenia, bipolar disorder, and depression. This phenomenon was exemplified by our delineation of a 520-kbp deletion on chromosome 16p12.1 (OMIM 136570), which is associated with developmental delay and extensive phenotypic variability.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> Interestingly, in most cases, this deletion was inherited from a parent who also manifested mild neuropsychiatric features, and the severely affected children were more likely to carry another large (&gt;500 kbp) rare CNV. We hypothesized that while each pathogenic primary variant sensitizes the genome to varying extents, additional rare variants in the genetic background modulate the ultimate clinical manifestation.</p>
<p id="Par6">Recent studies have identified secondary disease-associated variants that explain atypical clinical presentations of individuals carrying a primary variant.<sup><xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup> While these studies have explained phenotypic variability on a case-by-case basis, the global effect of the genetic background toward phenotypic variability among individuals sharing the same pathogenic variant has not been assessed. In this study, we evaluated 757 probands and 233 family members carrying primary variants associated with neurodevelopmental disease (17 rare CNVs or pathogenic variants in 301 genes). A comparison of the genetic background between probands and parents or siblings showed that in the presence of the same primary variant, variability and severity of neurodevelopmental disease correlates with the number of other rare variants, suggesting a global role of the genetic background toward phenotypic heterogeneity.</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="Sec3">
<title>Cohorts analyzed</title>
<p id="Par7">We analyzed clinical and genetic data in five subgroups of individuals carrying a disease-associated primary variant (Fig. <xref ref-type="fig" rid="Fig1">1</xref>): (1) 26 probands, 23 carrier parents and available family members carrying 16p12.1 deletion; (2) 53 autism probands from the Simons Simplex Collection (SSC) cohort who carry rare CNVs associated with syndromic and variably expressive genomic disorders;<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> (3) 84 probands and available family members with 16p11.2 BP4-BP5 deletion from the Simons Variation in Individuals Project (SVIP) cohort; (4) 295 autism probands from the SSC cohort reported to carry severe de novo loss-of-function variants in neurodevelopmental genes;<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> and (5) 184 probands and matched unaffected siblings from the SSC cohort who inherited the same rare (≤0.1% frequency) loss-of-function or likely damaging missense primary variants (CADD ≥25) in genes recurrently disrupted in neurodevelopmental disorders.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup><fig id="Fig1"><label>Fig. 1</label><caption><p><bold>Strategy for understanding the role of the genetic background in phenotypic variability of neurodevelopmental disease.</bold> (<bold>a</bold>) Schematic of primary variants and other hits used in this study. Disease-associated variants shared among different individuals were considered as “primary variants” (blue box), and rare likely deleterious single-nucleotide variants (SNVs) or copy-number variants (CNVs) affecting functionally intolerant genes were defined as “other hits” (blue Xs). Individuals with a higher burden of other hits (in red) exhibit a more severe clinical manifestation compared with those carrying the same primary variant but with a lower number of other hits (in gray). (<bold>b</bold>) Combined clinical and genomic analysis of 757 probands and 233 family members carrying primary disease-associated variants (16p12.1 deletion, 16p11.2 deletion, 16 rare CNVs, <italic>de novo</italic> pathogenic variants in autism simplex cases, and inherited pathogenic variants in disease-associated genes) was performed to understand the role of rare (≤0.1%) likely deleterious variants (SNVs with CADD ≥25 and CNVs) in functionally intolerant genes (Residual Variation Intolerance Score [RVIS] ≤20th percentile) toward the variable manifestation of neurodevelopmental disease. <italic>SRS</italic> Social Responsiveness Scale</p></caption><graphic id="d29e1194" xlink:href="41436_2018_266_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec4">
<title>Patient recruitment and clinical data ascertainment</title>
<p id="Par8">We obtained clinical and/or genomic data from 141 children carrying the 16p12.1 deletion, as well as 39 deletion carrier and 30 noncarrier parents. Probands and parents recruited through direct contact provided consent according to the protocol reviewed and approved by The Pennsylvania State University Institutional Review Board (IRB). When individuals were not contacted directly, de-identified phenotypic and genomic data were used; as such, these cases were exempt from IRB review and conformed to the Helsinki Declaration.</p>
<p id="Par9">We extracted clinical information from medical records or clinical questionnaires completed by different physicians from 180 carrier individuals and available family members (<xref ref-type="media" rid="MOESM1">Supplementary Method 1.1</xref>). We used a modified de Vries scoring system for quantifying the number and severity of phenotypic abnormalities in affected children, which allows for a uniform assessment of developmental phenotypes from clinical records (Table S<xref ref-type="media" rid="MOESM1">1</xref>).<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> Family history information was used to bin families with the deletion into strong and mild or negative family history categories based on the severity of neurodevelopmental or psychiatric features (Fig. S<xref ref-type="media" rid="MOESM1">1</xref>, <xref ref-type="media" rid="MOESM1">Supplementary Method 1.1</xref>). Genomic and clinical data for SSC and SVIP cohort families were obtained from the Simons Foundation Autism Research Initiative (SFARI) following appropriate approvals (see <xref ref-type="media" rid="MOESM1">Supplementary Method 1.1</xref>).</p>
</sec>
<sec id="Sec5">
<title>Burden analysis of rare variants in the genetic background (“other hits”)</title>
<p id="Par10">To identify all coding variants modulating the presentation of the 16p12.1 deletion, we performed exome sequencing and single-nucleotide polymorphism (SNP) arrays on 105 individuals from 26 families as previously reported (<xref ref-type="media" rid="MOESM1">Supplementary Method 1.2</xref>). Variant calls (SNVs and CNVs) from 716 individuals in the SSC were obtained from exome and SNP microarray studies,<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> and variant call files (VCF) and SNP array data from 84 families with 16p11.2 BP4-BP5 deletion were obtained from the Simons Foundation. We defined “rare variants” or “other hits” as additional rare likely deleterious variants (includes ≤0.1% frequency CNV or SNV with CADD ≥25) (ref. <sup><xref ref-type="bibr" rid="CR20">20</xref></sup>) affecting a functionally intolerant gene (RVIS ≤20th percentile) co-occurring in an individual who already carries a disease-associated primary variant (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>, <xref ref-type="media" rid="MOESM1">Supplementary Method 1.2</xref>). The Residual Variation Intolerance Score (RVIS) has been shown to be a good predictor of gene intolerance to deleterious variants and has been widely used by multiple studies for the recapitulation of known and the discovery of novel disease-associated genes.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> The biological function of genes with other hits was analyzed using Ingenuity Pathway Analysis (IPA, Qiagen Bioinformatics), expression data derived from the GTEx consortium,<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> and Gene Ontology (GO) enrichment analysis<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> (<xref ref-type="media" rid="MOESM1">Supplementary Method 1.3</xref>).</p>
</sec>
</sec>
<sec id="Sec6" sec-type="results">
<title>Results</title>
<sec id="Sec7">
<title>Rare variants in the genetic background and disease expressivity in 16p12.1 deletion probands</title>
<p id="Par11">We assessed how rare likely deleterious variants in the genetic background can modulate phenotypes in concert with a primary variant by evaluating 757 affected probands and 233 family members carrying disease-associated variants (rare CNVs or pathogenic SNVs) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>, see Methods). Using the 16p12.1 deletion as a paradigm for studying the genetic basis of variable expression of disease traits, we analyzed 180 individuals with the deletion and their noncarrier family members (Fig. <xref ref-type="fig" rid="Fig1">1b</xref>). The 16p12.1 deletion was inherited in 92.4% of cases, with a significant maternal bias (57.6% maternal [<italic>n</italic>=53] vs. 34.8% paternal [<italic>n</italic>=32], one-tailed binomial test <italic>p</italic>=0.01) (Table S<xref ref-type="media" rid="MOESM1">2</xref>). In accordance with the female protective model described for neurodevelopmental disorders,<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup> we observed a significant gender bias among probands with the 16p12.1 deletion (67.9% males vs. 32.1% females, one-tailed binomial test <italic>p</italic>&lt;0.0001). Detailed clinical analysis of 141 affected children with 16p12.1 deletion showed a wide heterogeneity of phenotypes, with a high prevalence of neurodevelopmental, craniofacial, and musculoskeletal features (&gt;50%), and variable involvement of other organs and systems (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>, Table S<xref ref-type="media" rid="MOESM6">3</xref>). In contrast, 32 of 39 (82%) (61.5% females, 38.5% males) carrier parents showed mild cognitive, behavioral, and/or psychiatric features (Table S<xref ref-type="media" rid="MOESM1">4</xref>), consistent with previous reports of cognitive impairment and increased risk for schizophrenia in carriers of the 16p12.1 deletion.<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup><fig id="Fig2"><label>Fig. 2</label><caption><p><bold>Rare variants in the genetic background contribute to the phenotypic heterogeneity in 16p12.1 deletion.</bold> (<bold>a</bold>) Phenotypic spectrum of 16p12.1 deletion in probands (<italic>n</italic>=141, red) and carrier parents (<italic>n</italic>=39, gray). Probands exhibit a spectrum of severe developmental features compared with the mild cognitive and psychiatric features observed in carrier parents. Features represented were observed in ≥5% of probands or carrier parents. (<bold>b</bold>) Example of families with inherited 16p12.1 deletion. Family 1 (left) shows three generations carrying 16p12.1 deletion and multiple neurodevelopmental and psychiatric features, with the proband (P1C_01, indicated with arrow) carrying a de novo loss-of-function variant in <italic>SETD5</italic> (p.Asp542Thrfs*3) and a stopgain variant in <italic>DMD</italic> gene (p.Trp3X) inherited from the mother without the 16p12.1 deletion (noncarrier). Family 2 (right) shows a proband (PC_11, indicated with arrow) with multiple congenital and neurodevelopmental features carrying 16p12.1 deletion and 2p16.3 deletion (encompassing <italic>NRXN1</italic>), the latter inherited from the noncarrier mother. (<bold>c</bold>) Analysis of rare (≤0.1%) likely deleterious variants (single-nucleotide variants with CADD ≥25) in genes intolerant to functional variation (RVIS ≤20th percentile) in proband–carrier parent pairs shows that probands present a higher burden of other hits compared with their carrier parents (<italic>n</italic>=23, Wilcoxon signed-rank test, <italic>p</italic>=0.004). <italic>ADHD</italic> attention deficit hyperactivity disorder</p></caption><graphic id="d29e1369" xlink:href="41436_2018_266_Fig2_HTML"></graphic></fig></p>
<p id="Par12">To identify variants within protein-coding regions that contribute to a more severe manifestation of the deletion in the affected children compared with their carrier parents, we performed exome sequencing and high-resolution SNP arrays in 26 families (<italic>n</italic>=105) with 16p12.1 deletion (23 inherited and 3 de novo cases, Table S<xref ref-type="media" rid="MOESM1">5</xref>). We first evaluated whether the deletion could unmask recessive alleles, and found no rare pathogenic variants within the seven 16p12.1 genes on the nondeleted chromosome (Table S<xref ref-type="media" rid="MOESM1">6</xref>). We next performed a case-by-case analysis of families for other hits elsewhere in the genome by focusing on rare CNVs (≤0.1%, ≥50 kbp), de novo or rare (ExAC frequency ≤0.1%) loss-of-function (LoF) variants, and rare likely damaging missense variants (Phred-like CADD ≥25) in disease-associated genes (see Methods, Tables S<xref ref-type="media" rid="MOESM1">7</xref>–S<xref ref-type="media" rid="MOESM7">9</xref>). For example, we identified two disease-associated variants in proband P1C_01, including a de novo LoF variant in the intellectual disability–associated gene <italic>SETD5</italic> (OMIM 615761, c.1623_1624insAC, p.Asp542Thrfs*3) and a LoF variant in <italic>DMD</italic> (OMIM 310200, c.9G&gt;A, p.Trp3X) transmitted from the non-16p12.1-deletion carrier mother (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>). Similarly, a rare deletion at 2p16.3 encompassing <italic>NRXN1</italic> (OMIM 614332), inherited from the noncarrier mother, was identified in proband PC_11 (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>).</p>
<p id="Par13">While private disease-associated variants may explain the variable and severe features in the affected children on a case-by-case basis, we lacked the statistical power to implicate individual genes or variants that modulate specific 16p12.1 deletion phenotypes. Therefore, to globally assess the genome-wide contribution of rare likely deleterious variants affecting functionally relevant genes, we performed an integrative analysis and quantified rare (frequency ≤0.1%), likely deleterious variants (CNVs or SNVs with CADD ≥25) within genes intolerant to functional variation (RVIS ≤20th percentile),<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> hereafter referred to as the “burden of other hits.” Intrafamilial comparison showed that probands have an excess of other hits compared with their carrier parents (Wilcoxon signed-rank test, <italic>p</italic>=0.004, Fig. <xref ref-type="fig" rid="Fig2">2c</xref> and S<xref ref-type="media" rid="MOESM1">2</xref>), with no change in the number of synonymous variants in all genes (<italic>p</italic>=0.29) or in RVIS ≤20th genes (<italic>p</italic>=0.36, Fig. S<xref ref-type="media" rid="MOESM1">2E, F</xref>). Further, functional analysis of genes with other hits showed that probands presented an excess of genes that were preferentially expressed in the human brain (Wilcoxon signed-rank test, <italic>p</italic>=0.04, Fig. S<xref ref-type="media" rid="MOESM1">3</xref>) and enriched for developmental pathways (Table S<xref ref-type="media" rid="MOESM1">10</xref>) compared with carrier parents.</p>
<p id="Par14">The severity and variability of neurodevelopmental features is contingent upon family history of neuropsychiatric disease.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> In fact, the cognitive and social outcomes in probands with de novo 16p11.2 BP4-BP5 deletion or 22q11.2 deletions have been reported to positively correlate with the cognitive and social skills of their parents.<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup> However, the genetic basis of such background effects has not been specifically studied. We assessed the role of other hits toward family-specific background effects and in the observed interfamilial variability of clinical features in probands with 16p12.1 deletion. We found that probands with a strong family history of neurodevelopmental and psychiatric disease presented a more severe and heterogeneous clinical presentation (Mann–Whitney one-tailed, <italic>p</italic>=0.04) and a higher burden of other hits (<italic>p</italic>=0.001) than those with mild or negative family history (Figs. <xref ref-type="fig" rid="Fig3">3a–c</xref> and S<xref ref-type="media" rid="MOESM1">4A–C</xref>). Interestingly, probands with a strong family history also showed a higher difference in burden compared with their carrier parents than probands with a mild family history (<italic>p</italic>=0.003, Fig. <xref ref-type="fig" rid="Fig3">3d</xref>). While we did not observe a difference in burden between carrier parents based on family history (<italic>p</italic>=0.68, Fig. S<xref ref-type="media" rid="MOESM1">4B</xref>), we found that noncarrier parents with a strong family history presented a significantly higher burden compared with those with a mild family history (<italic>p</italic>=0.01, Fig. <xref ref-type="fig" rid="Fig3">3e</xref>). Therefore, in families with a strong history of neurodevelopmental and psychiatric disease, a higher number of rare variants in the genetic background are more likely to be transmitted to the proband from the noncarrier parent, potentially contributing to a more severe manifestation of the disorder. These results suggest a potential role for rare variants in the genetic background in modulating intra- and interfamilial clinical variability observed in families with the 16p12.1 deletion.<fig id="Fig3"><label>Fig. 3</label><caption><p><bold>Strong family history of neurodevelopmental and psychiatric disease is associated with an excess of other hits and severe phenotypic outcome in 16p12.1 deletion probands.</bold> (<bold>a</bold>) Diagram showing phenotypic heterogeneity in 16 probands with 16p12.1 deletion (black=phenotype present, white=absent, gray=not assessed) and their family history of neurodevelopmental and psychiatric disease (red=strong, blue=mild/negative). Probands with strong family history (<italic>n</italic>=9) have (<bold>b</bold>) a more heterogeneous clinical manifestation (higher de Vries scores, one-tailed Mann–Whitney, <italic>p</italic>=0.04) and (<bold>c</bold>) a higher burden of other hits (one-tailed Mann–Whitney <italic>p</italic>=0.001) than those with mild or negative family history (<italic>n</italic>=7). (<bold>d</bold>) Probands with a strong family history exhibit a greater difference in burden of other hits compared with carrier parents (<italic>p</italic>=0.003). (<bold>e</bold>) Noncarrier parents from families with strong family history present a higher burden compared with those with mild/negative family history (one-tailed Mann–Whitney, <italic>p</italic>=0.01). <italic>NC</italic> Noncarrier</p></caption><graphic id="d29e1536" xlink:href="41436_2018_266_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="Sec8">
<title>Burden of other rare variants correlates with quantitative phenotypes among individuals with 16p11.2 deletion and other rare pathogenic CNVs</title>
<p id="Par15">We next assessed whether the burden of other rare variants modulates quantitative phenotypes in carriers of other CNVs associated with neurodevelopmental phenotypes (Fig. <xref ref-type="fig" rid="Fig1">1b</xref>). In autism probands with disease-associated rare CNVs (<italic>n</italic> = 53, Table S<xref ref-type="media" rid="MOESM1">11</xref>) from the Simons Simplex Cohort (SSC), we observed a modest but significant negative correlation (Pearson correlation, <italic>R</italic> = –0.36, <italic>p</italic> = 0.004) between the number of other hits and full-scale IQ (FSIQ) scores (Fig. <xref ref-type="fig" rid="Fig4">4a</xref>). This result held true when we separately analyzed individuals carrying 16p11.2 BP4-BP5 deletion (<italic>R</italic> = –0.68, <italic>p</italic> = 0.04), but did not show statistical significance for 16p11.2 BP4-BP5 duplication (<italic>R</italic> = –0.34, p = 0.17), 1q21.1 duplication (<italic>R</italic> = –0.36, <italic>p</italic> = 0.32), or 7q11.23 duplication (<italic>R</italic> = –0.74, <italic>p</italic> = 0.17), potentially due to low sample sizes (Figs. <xref ref-type="fig" rid="Fig4">4a</xref> and S<xref ref-type="media" rid="MOESM1">5</xref>). Interestingly, probands with disease-associated CNVs and intellectual disability (FSIQ &lt;70) showed a significant increase in the number of other hits compared with those without intellectual disability (FSIQ ≥70, one-tailed Mann–Whitney, <italic>p</italic>=0.02, Fig. S<xref ref-type="media" rid="MOESM1">6</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p><bold>Burden of other hits modulates quantitative phenotypes among probands with a first-hit copy-number variant (CNV) or single-nucleotide variant (SNV) associated with neurodevelopmental disease.</bold> (<bold>a</bold>) Negative correlation between the number of other hits and full-scale IQ (FSIQ) scores in individuals (<italic>n</italic> = 53) carrying 16 CNVs associated with neurodevelopmental disease (Pearson correlation, <italic>R</italic> = –0.36, <italic>p</italic> = 0.004). Probands with 16p11.2 deletion (red), 16p11.2 duplication (green), 1q21.1 duplication (blue) and 7q11.23 duplication (yellow) are highlighted, while gray circles represent probands with other rare CNVs. (<bold>b</bold>) Higher burden of other hits among probands with 16p11.2 deletion and FSIQ &lt;70 (<italic>n</italic> = 17) compared with probands with FSIQ ≥70 (<italic>n</italic> = 65, one-tailed Mann–Whitney, <italic>p</italic> = 0.08). (<bold>c</bold>) Negative correlation between the number of other hits and head circumference z-scores (age ≥12 months, <italic>n</italic> = 80, Pearson correlation <italic>R</italic> = –0.26, <italic>p</italic> = 0.009) in probands with 16p11.2 deletion. (<bold>d</bold>) Autism probands with de novo disruptive variants and available FSIQ scores (<italic>n</italic> = 290) show a moderate negative correlation (Spearman correlation coefficient, <italic>R</italic> = –0.25, <italic>p</italic> &lt; 0.0001) between the number of other hits and FSIQ scores. (<bold>e</bold>) Probands present an excess of other hits compared with their unaffected siblings (<italic>n</italic> = 184 pairs) carrying the same inherited pathogenic variants (loss-of-function or damaging missense CADD ≥25) in genes recurrently disrupted in neurodevelopmental disease (Wilcoxon signed-rank test, <italic>p</italic> = 0.03). (<bold>f</bold>) Enrichment of other hits among individuals with damaging variants in <italic>SCN1A</italic> (loss-of-function or missense CADD ≥25) and intellectual disability (one-tailed Mann–Whitney, <italic>p</italic> = 0.02) compared with those without intellectual disability</p></caption><graphic id="d29e1675" xlink:href="41436_2018_266_Fig4_HTML"></graphic></fig></p>
<p id="Par16">We further expanded our analysis by evaluating a larger set of 84 families with 16p11.2 BP4-BP5 deletion from the Simons Variation in Individuals Project (SVIP). We observed a higher median number of other hits in probands carrying the 16p11.2 deletion that had intellectual disability (FSIQ &lt;70, median=8) compared with those with no intellectual disability (FSIQ ≥70, median=7 one-tailed Mann–Whitney, <italic>p</italic> = 0.08, Fig. <xref ref-type="fig" rid="Fig4">4b</xref>), without a difference in the number of synonymous variants between the two subgroups (median of 9957 synonymous changes for FSIQ &lt;70 group versus 10,052 for the FSIQ ≥70 group, two-tailed Mann–Whitney, <italic>p</italic> = 0.51, Fig. S<xref ref-type="media" rid="MOESM1">7A</xref>). Notably, we observed only a mild negative correlation between the burden of other hits and FSIQ, which did not attain statistical significance (Pearson correlation, <italic>R</italic> = –0.16, <italic>p</italic> = 0.08, Fig. S<xref ref-type="media" rid="MOESM1">7B</xref>). Even though the sample size in the SSC cohort (<italic>n</italic> = 8) is small, we hypothesized that this marginal significance compared with 16p11.2 deletion probands from the SSC cohort (Figs. <xref ref-type="fig" rid="Fig4">4a</xref> and S<xref ref-type="media" rid="MOESM1">5B</xref>) could be due to differences in clinical ascertainment. The SVIP cohort was selected for individuals carrying a 16p11.2 deletion who manifested a more heterogeneous set of phenotypes, while individuals from the SSC cohort were specifically ascertained for idiopathic autism.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> These differences in ascertainment were evident by different distributions of quantitative phenotypes, including body mass index (BMI), FSIQ, and SRS T-scores, in both populations (Fig. S<xref ref-type="media" rid="MOESM1">8</xref>).</p>
<p id="Par17">After adjusting for age to allow for full manifestation of the head phenotype, we identified a negative correlation between the number of other hits in SVIP probands with 16p11.2 deletion and their head circumference (HC) z-scores (age ≥12 months, <italic>n</italic> = 80, Pearson’s <italic>R</italic> = –0.26, <italic>p</italic> = 0.009, Fig. <xref ref-type="fig" rid="Fig4">4c</xref>).<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup> The observation that HC z-scores decline steadily (from &gt;2 to &lt;–2 scores) as other hits accumulate confirms that the deletion primarily leads to macrocephaly phenotypes, and suggests that rare variants in the genetic background could explain the incomplete penetrance of this phenotype among carriers of the deletion.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> We note that the burden of other hits did not correlate with Social Responsiveness Scale (SRS) T-scores or body mass index (BMI) z-scores, measures for autism and obesity, among probands with rare CNVs from the SSC cohort (Fig. S<xref ref-type="media" rid="MOESM1">9A, B</xref>) or those with 16p11.2 deletion from the SVIP cohort (Fig. S<xref ref-type="media" rid="MOESM1">9C, D</xref>), suggesting other mechanisms for the variability of these phenotypes.</p>
</sec>
<sec id="Sec9">
<title>Rare variants in the genetic background modulate disease manifestation among individuals with disruptive variants in disease-associated genes</title>
<p id="Par18">We next analyzed 295 autism simplex cases from the SSC cohort with previously identified de novo gene-disruptive variants within 271 genes,<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> and observed a moderately negative correlation between the burden of other hits and FSIQ scores (Spearman’s correlation, <italic>R</italic> = –0.25, <italic>p</italic> &lt; 0.0001, Fig. <xref ref-type="fig" rid="Fig4">4d</xref>). Within this cohort, individuals with intellectual disability (FSIQ &lt;70, <italic>n</italic> = 93) presented an enrichment of other hits compared with those without intellectual disability (FSIQ ≥70, <italic>n</italic> = 197) (one-tailed Mann–Whitney, <italic>p</italic> = 0.001, Fig. S<xref ref-type="media" rid="MOESM1">10A</xref>). We did not observe a role for the burden of other hits in modulating BMI z-scores (Spearman’s <italic>R</italic> = –0.038, <italic>p</italic> = 0.27, Fig. S<xref ref-type="media" rid="MOESM1">10B</xref>), although we did find a mild but significant positive correlation with SRS T-scores (Spearman’s <italic>R</italic> = 0.12, <italic>p</italic> = 0.02, Fig. S<xref ref-type="media" rid="MOESM1">10C</xref>). Moreover, when probands were separated by gender, we observed a higher burden of other hits in females compared with males (one-tailed Mann–Whitney, <italic>p</italic>=0.02, Fig. S<xref ref-type="media" rid="MOESM1">11</xref>). This supports the hypothesis that females require a higher contribution from the genetic background to reach the genetic threshold for pathogenesis of neurodevelopmental disease than males.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup></p>
<p id="Par19">While there is a consensus on the pathogenic role of de novo gene-disruptive variants in simplex families, the interpretation of inherited pathogenic variants within the same genes is challenging. To understand the role of the genetic background in the penetrance of inherited disruptive variants in disease-associated genes, we analyzed 184 pairs of autism probands and unaffected siblings who inherited the same pathogenic variant in genes recurrently disrupted in neurodevelopmental disorders (Table S<xref ref-type="media" rid="MOESM2">12</xref>). We found a greater enrichment of other hits in probands compared with their unaffected siblings (Wilcoxon signed-rank test <italic>p</italic> = 0.03, Fig. <xref ref-type="fig" rid="Fig4">4e</xref>), suggesting that rare variants likely contribute to increased penetrance of neurodevelopmental phenotypes in children with inherited pathogenic single-gene variants. When we analyzed probands carrying pathogenic variants in specific neurodevelopmental genes, we found that the severity of cognitive deficits in individuals with damaging variants in <italic>SCN1A</italic> was concordant with an excess of other hits (probands with FSIQ &lt;70, <italic>n</italic> = 8, median=16.5, versus those with FSIQ ≥70, <italic>n</italic> = 8, median=8.5, one-tailed Mann–Whitney, <italic>p</italic> = 0.02) (Fig. <xref ref-type="fig" rid="Fig4">4f</xref>). This observation could also explain the diversity of other phenotypes co-occurring with the disruption of the epilepsy-associated <italic>SCN1A</italic> gene, such as motor delay and autism.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup></p>
</sec>
<sec id="Sec10">
<title>Other hits involve disease-associated genes and affect core cellular and developmental processes</title>
<p id="Par20">To understand how other rare variants could modulate phenotypes among probands with pathogenic first-hit variants, we explored the functionality of genes with other hits identified in all probands analyzed in our study. Overall, we identified 3197 other hits encompassing a diverse set of 1615 functionally intolerant genes. Of these, 40.9% (660/1615) were found to be extremely intolerant to loss-of-function variants (probability of loss-of-function intolerance [pLI] metric ≥0.9). These genes were also enriched for postsynaptic density genes, genes encoding FMRP targets, chromatin-associated genes, embryonically expressed genes, and essential genes compared with the whole genome (52% vs. 26%, Chi-squared test, <italic>p</italic>&lt;0.0001).<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup> Interestingly, 44 of these genes with other hits (such as <italic>CNTNAP2</italic>, <italic>MBD5</italic>, <italic>SCN1A</italic>, <italic>CHD8</italic>, and <italic>AUTS2</italic>) have been recurrently associated with neurodevelopmental disorders<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> (Fig. S<xref ref-type="media" rid="MOESM1">12</xref>), 58 genes have been previously identified as a causative gene in simplex autism cases<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> (Table S<xref ref-type="media" rid="MOESM1">13</xref>), and 50 genes have been associated with skeletal, muscular, cardiovascular, or renal disorders, as classified in the human disease network (Table S<xref ref-type="media" rid="MOESM3">14</xref>).<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> We further assessed the location of other-hit variants within a subset of genes recurrently associated with disease, including <italic>RIMS1</italic>, <italic>DIP2A</italic>, <italic>KDM5B</italic>, and <italic>ACOX2</italic>, and found no specificity for the location of the other hits within the protein sequences compared with previously reported de novo pathogenic variants within these genes (Fig. <xref ref-type="fig" rid="Fig5">5a</xref>). In fact, in some cases, we observed stopgain variants that were more premature in the protein sequence than previously reported pathogenic variants, suggesting that the other hit can potentially exert as severe an effect as a primary variant, if these are true loss-of-function variants. The allelic diversity of other likely deleterious variants within these genes suggests that further functional analysis should be performed to understand their specific effects on modulating developmental phenotypes.<fig id="Fig5"><label>Fig. 5</label><caption><p><bold>Rare variants in the genetic background affect core biological processes and disease-associated genes.</bold> (<bold>a</bold>) Examples of nonspecificity in the location of other hits in protein domains compared with first-hits. Location of variants in the protein sequences of <italic>RIMS1</italic>, <italic>DIP2A</italic>, <italic>KDM5B</italic> and <italic>ACOX2</italic>, genes with other hits (green arrows) and previously reported de novo disruptive variants in simplex autism cases (red arrows). Genes with other hits found in (<bold>b</bold>) autism spectrum disorder (ASD) probands carrying de novo disruptive variants (Simons Simplex Cohort; SSC) and (<bold>c</bold>) probands with the 16p11.2 deletion (Simons Variation in Individuals Project; SVIP) are enriched in core biological processes (FDR &lt;0.05 with Bonferroni correction). Clusters of enriched Gene Ontology (GO) terms for “developmental processes,” “cell signaling,” “cell adhesion,” and “transport” functions are present among other hits found in each cohort. The size of each circle represents the number of genes annotated for each GO term; red shading of each circle represents the FDR for enrichment of each GO term among genes with other hits, with darker shades indicating a lower FDR. Line thickness represents the number of shared genes between pairs of GO terms. FDR values of the enriched GO terms are detailed in Tables S15-S16. <italic>FDR</italic> False discovery rate</p></caption><graphic id="d29e1951" xlink:href="41436_2018_266_Fig5_HTML"></graphic></fig></p>
<p id="Par21">To further understand the functional role of genes carrying rare variants, we performed Gene Ontology enrichment analysis of genes with other hits in probands with de novo pathogenic variants from the SSC and 16p11.2 deletion probands from the SVIP cohort. We found that genes carrying other hits in probands from both cohorts were enriched for core processes, including cell signaling, cell adhesion, and developmental processes (Fig. <xref ref-type="fig" rid="Fig5">5b, c</xref>, Tables S<xref ref-type="media" rid="MOESM1">15</xref>, S<xref ref-type="media" rid="MOESM1">16</xref>). Although some of these genes have been individually associated with a disease phenotype, further functional analyses are required to understand potential interactions between genes affected by both primary variants and other hits, their cumulative burden, and ultimately their potential contribution toward phenotypic variability.</p>
</sec>
</sec>
<sec id="Sec11" sec-type="discussion">
<title>Discussion</title>
<p id="Par22">In this study, we have explored the contribution of rare variants in the genetic background toward the phenotypic heterogeneity of disease-associated variants. Recently, exome and genome sequencing studies have reported an increased burden of rare deleterious variants toward risk for neurodevelopmental disorders<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup> and combined parent-of-origin inherited risk effects for autism.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup> Our analysis supports a complex model for neurodevelopmental disorders, and further postulates how rare variants in the genetic background modulate specific phenotypes in the presence of the same disease-causing variant.<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup> We propose that a higher burden of rare variants increases the likelihood of involving a modifier gene within disease-related pathways, as well as allows for a higher number of oligogenic combinations potentially modulating the phenotype associated with the first hit. Some primary variants more tolerant to changes in the genetic background, such as the 16p12.1 deletion, are transmitted through generations and only surpass the threshold for severe disease with the accumulation of several additional rare pathogenic variants. Other primary variants that are often de novo, such as the 16p11.2 deletion, push the genetic background closer to the threshold for severe manifestation and therefore require a lesser contribution from other hits. Similarly, highly penetrant syndromic CNVs such as Smith–Magenis syndrome and Sotos syndrome, which are mostly de novo and encompass genes more intolerant to functional variation compared with variably expressive CNVs (<italic>p</italic>=0.03, one-tailed Mann–Whitney, Table S<xref ref-type="media" rid="MOESM1">17</xref>, Fig. S<xref ref-type="media" rid="MOESM1">13</xref>), would push the genetic liability beyond the threshold for severe disease on their own.<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup> While additional variants may not be necessary for complete penetrance of these disorders, these variants can modify specific phenotype traits when present. For example, deleterious variants in histone modifier genes have been reported to contribute to heart defects in 22q11.2 deletion syndrome.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> This model would also apply for single-gene disorders, where other hits potentially explain discordant clinical features reported among affected carriers of the same molecular alteration, as described for Rett syndrome and individuals with pathogenic variants in the intellectual disability gene <italic>PACS1</italic>.<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup></p>
<p id="Par23">Our observations that probands with a strong family history exhibit severe clinical manifestation and a higher burden of other hits also provide insights into the role of rare variants in the genetic background toward the reported correlation between parental profiles and clinical outcome in probands carrying rare CNVs.<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup> Moreover, the observed higher burden of other hits in the noncarrier parents in families with strong family history suggests assortative mating, and transmission of these hits to the proband potentially explains the increased clinical severity. Similarly, in 16p11.2 deletion, we observed that children who inherited the CNV presented lower FSIQ scores (<italic>n</italic>=8, median FSIQ=75) than probands with a de novo deletion (<italic>n</italic>=57, median FSIQ=85, one-tailed Mann–Whitney, <italic>p</italic>=0.006, Fig. S<xref ref-type="media" rid="MOESM1">14A</xref>), in agreement with previous reports.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> This was also consistent with a nonsignificant excess of other hits among probands with an inherited 16p11.2 deletion (one-tailed Mann–Whitney, <italic>p</italic>=0.06, Fig. S<xref ref-type="media" rid="MOESM1">14B</xref>) compared with probands with a de novo deletion. These results highlight the importance of eliciting family history of psychiatric and neurodevelopmental disease for more accurate diagnostic assessment of the affected children.</p>
<p id="Par24">Overall, our results suggest a multidimensional effect of rare variants in the genetic background toward clinical features, and their contribution to specific phenotypic domains depends on the extent to which the primary variant sensitizes an individual toward a specific phenotypic trajectory. An important observation from our study is that a large number of disease-associated variants deemed to be solely causative for the disorder are in fact accompanied by a substantial amount of rare genetic variation. Longitudinal and quantitative phenotyping across multiple developmental domains in all family members, along with genome sequencing studies in affected and seemingly asymptomatic individuals with a primary variant, are necessary for a more accurate understanding of these complex disorders. Therefore, it is critical that even after identifying a likely diagnostic pathogenic variant, further analysis of the genetic background must be performed to provide appropriate counseling and management.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec13">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41436_2018_266_MOESM1_ESM.pdf"><caption><p>Supplementary Method</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41436_2018_266_MOESM2_ESM.xlsx"><caption><p>Supplementary Table 12</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41436_2018_266_MOESM3_ESM.xlsx"><caption><p>Supplementary Table 14</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41436_2018_266_MOESM4_ESM.xlsx"><caption><p>Supplementary Table 18</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41436_2018_266_MOESM5_ESM.xlsx"><caption><p>Supplementary Table 19</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41436_2018_266_MOESM6_ESM.xlsx"><caption><p>Supplementary Table 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41436_2018_266_MOESM7_ESM.xlsx"><caption><p>Supplementary Table 9</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1038/s41436-018-0266-3) contains supplementary material, which is available to authorized users.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by NIH R01-GM121907, Brain and Behavior Foundation (NARSAD 22535), SFARI Pilot Grant (SFARI 399894, S.G.) and resources from the Huck Institutes of the Life Sciences to S.G. L.P. was supported by Fulbright Commission Uruguay–ANII and the Huck Institutes of the Life Sciences. M.J. was supported by NIH T32-GM102057. C.R., L.C., O.G., and E.A. were supported by the Italian Ministry of Health and “5 per mille” funding. K.M. is a Jacobs Foundation Research Fellow. A.R. is supported by the Swiss National Science Foundation (31003A_160203). Dedicated to the memory of Ethan Francis Schwartz, 1996–1998. We are grateful to all of the families in each cohort (16p12.1 deletion, SVIP and SSC) who participated in the study. We thank the SSC principal investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, R. Goin-Kochel, E. Hanson, D. Grice, A. Klin, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, K. Pelphrey, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z. Warren, E. Wijsman) as well as the Simons VIP Consortium. We appreciate obtaining access to genomic and phenotypic data on SFARI Base. Approved researchers can obtain the SSC and SVIP population data sets described in this study by applying at <ext-link ext-link-type="uri" xlink:href="https://www.base.sfari.org">https://www.base.sfari.org</ext-link>.</p>
</ack>
<notes notes-type="COI-statement">
<title>Disclosure</title>
<p id="Par25">The authors declare no conflicts of interest.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vorstman</surname>
<given-names>JAS</given-names>
</name>
<name>
<surname>Parr</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Moreno-De-Luca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Anney</surname>
<given-names>RJL</given-names>
</name>
<name>
<surname>Nurnberger</surname>
<given-names>JI</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Hallmayer</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Autism genetics: opportunities and challenges for clinical translation</article-title>
<source/>Nat Rev Genet
          <year>2017</year>
<volume>18</volume>
<fpage>362</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.1038/nrg.2017.4</pub-id>
<pub-id pub-id-type="pmid">28260791</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic heterogeneity of genomic disorders and rare copy-number variants</article-title>
<source/>New Engl J Med
          <year>2012</year>
<volume>367</volume>
<fpage>1321</fpage>
<lpage>1331</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1200395</pub-id>
<pub-id pub-id-type="pmid">22970919</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreno-De-Luca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Challman</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Moreno-De-Luca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Ledbetter</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence</article-title>
<source/>Lancet Neurol
          <year>2013</year>
<volume>12</volume>
<fpage>406</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(13)70011-5</pub-id>
<pub-id pub-id-type="pmid">23518333</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mannik</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Magi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mace</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Copy number variations and cognitive phenotypes in unselected populations</article-title>
<source/>JAMA
          <year>2015</year>
<volume>313</volume>
<fpage>2044</fpage>
<lpage>2054</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2015.4845</pub-id>
<pub-id pub-id-type="pmid">26010633</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bijlsma</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gijsbers</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schuurs-Hoeijmakers</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Extending the phenotype of recurrent rearrangements of 16p11. 2: deletions in mentally retarded patients without autism and in normal individuals</article-title>
<source/>Eur J Med Genet
          <year>2009</year>
<volume>52</volume>
<fpage>77</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmg.2009.03.006</pub-id>
<pub-id pub-id-type="pmid">19306953</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Angelo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lebon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Defining the effect of the 16p11.2 duplication on cognition, behavior, and medical comorbidities</article-title>
<source/>JAMA Psychiatry
          <year>2016</year>
<volume>73</volume>
<fpage>20</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.2123</pub-id>
<pub-id pub-id-type="pmid">26629640</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reymond</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zufferey</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus</article-title>
<source/>Nature
          <year>2011</year>
<volume>478</volume>
<fpage>97</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1038/nature10406</pub-id>
<pub-id pub-id-type="pmid">21881559</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammer</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare variants of small effect size in neuronal excitability genes influence clinical outcome in Japanese cases of SCN1A truncation-positive Dravet syndrome</article-title>
<source/>PLoS One
          <year>2017</year>
<volume>12</volume>
<fpage>e0180485</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0180485</pub-id>
<pub-id pub-id-type="pmid">28686619</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Todarello</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kolachana</surname>
<given-names>BS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Incomplete penetrance of NRXN1 deletions in families with schizophrenia</article-title>
<source/>Schizophr Res
          <year>2014</year>
<volume>155</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2014.02.023</pub-id>
<pub-id pub-id-type="pmid">24680031</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>St Clair</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Blackwood</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association within a family of a balanced autosomal translocation with major mental illness</article-title>
<source/>Lancet
          <year>1990</year>
<volume>336</volume>
<fpage>13</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/0140-6736(90)91520-K</pub-id>
<pub-id pub-id-type="pmid">1973210</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>GM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A recurrent 16p12. 1 microdeletion supports a two-hit model for severe developmental delay</article-title>
<source/>Nat Genet
          <year>2010</year>
<volume>42</volume>
<fpage>203</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1038/ng.534</pub-id>
<pub-id pub-id-type="pmid">20154674</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karaca</surname>
<given-names>Ender</given-names>
</name>
<name>
<surname>Posey</surname>
<given-names>Jennifer E</given-names>
</name>
<name>
<surname>Coban Akdemir</surname>
<given-names>Zeynep</given-names>
</name>
<name>
<surname>Pehlivan</surname>
<given-names>Davut</given-names>
</name>
<name>
<surname>Harel</surname>
<given-names>Tamar</given-names>
</name>
<name>
<surname>Jhangiani</surname>
<given-names>Shalini N</given-names>
</name>
<name>
<surname>Bayram</surname>
<given-names>Yavuz</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Xiaofei</given-names>
</name>
<name>
<surname>Bahrambeigi</surname>
<given-names>Vahid</given-names>
</name>
<name>
<surname>Yuregir</surname>
<given-names>Ozge Ozalp</given-names>
</name>
<name>
<surname>Bozdogan</surname>
<given-names>Sevcan</given-names>
</name>
<name>
<surname>Yesil</surname>
<given-names>Gozde</given-names>
</name>
<name>
<surname>Isikay</surname>
<given-names>Sedat</given-names>
</name>
<name>
<surname>Muzny</surname>
<given-names>Donna</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>Richard A</given-names>
</name>
<name>
<surname>Lupski</surname>
<given-names>James R</given-names>
</name>
</person-group>
<article-title>Phenotypic expansion illuminates multilocus pathogenic variation</article-title>
<source/>Genetics in Medicine
          <year>2018</year>
<volume>20</volume>
<issue>12</issue>
<fpage>1528</fpage>
<lpage>1537</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2018.33</pub-id>
<pub-id pub-id-type="pmid">29790871</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Posey</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Harel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resolution of disease phenotypes resulting from multilocus genomic variation</article-title>
<source/>N Engl J Med
          <year>2017</year>
<volume>376</volume>
<fpage>21</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1516767</pub-id>
<pub-id pub-id-type="pmid">27959697</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaaf</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Sabo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders</article-title>
<source/>Hum Mol Genet
          <year>2011</year>
<volume>20</volume>
<fpage>3366</fpage>
<lpage>3375</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr243</pub-id>
<pub-id pub-id-type="pmid">21624971</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of de novo coding mutations to autism spectrum disorder</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>216</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature13908</pub-id>
<pub-id pub-id-type="pmid">25363768</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excess of rare, inherited truncating mutations in autism</article-title>
<source/>Nat Genet
          <year>2015</year>
<volume>47</volume>
<fpage>582</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3303</pub-id>
<pub-id pub-id-type="pmid">25961944</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Mantilla</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Moreno-De-Luca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ledbetter</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>A cross-disorder method to identify novel candidate genes for developmental brain disorders</article-title>
<source/>JAMA Psychiatry
          <year>2016</year>
<volume>73</volume>
<fpage>275</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.2692</pub-id>
<pub-id pub-id-type="pmid">26817790</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Vries</surname>
<given-names>B</given-names>
</name>
<name>
<surname>White</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical studies on submicroscopic subtelomeric rearrangements: a checklist</article-title>
<source/>J Med Genet
          <year>2001</year>
<volume>38</volume>
<fpage>145</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.38.3.145</pub-id>
<pub-id pub-id-type="pmid">11238680</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Willsey</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci</article-title>
<source/>Neuron
          <year>2015</year>
<volume>87</volume>
<fpage>1215</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.09.016</pub-id>
<pub-id pub-id-type="pmid">26402605</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kircher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Witten</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>P</given-names>
</name>
<name>
<surname>O'Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Shendure</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>
<source/>Nat Genet
          <year>2014</year>
<volume>46</volume>
<fpage>310</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2892</pub-id>
<pub-id pub-id-type="pmid">24487276</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrovski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Heinzen</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>DB</given-names>
</name>
</person-group>
<article-title>Genic intolerance to functional variation and the interpretation of personal genomes</article-title>
<source/>PLoS Genet
          <year>2013</year>
<volume>9</volume>
<fpage>e1003709</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1003709</pub-id>
<pub-id pub-id-type="pmid">23990802</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Consortium</surname>
<given-names>GT</given-names>
</name>
</person-group>
<article-title>The Genotype-Tissue Expression (GTEx) project</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<fpage>580</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2653</pub-id>
<pub-id pub-id-type="pmid">23715323</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muruganujan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Casagrande</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>PD</given-names>
</name>
</person-group>
<article-title>Large-scale gene function analysis with the PANTHER classification system</article-title>
<source/>Nat Protoc
          <year>2013</year>
<volume>8</volume>
<fpage>1551</fpage>
<lpage>1566</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2013.092</pub-id>
<pub-id pub-id-type="pmid">23868073</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Hersch</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A higher mutational burden in females supports a “female protective model” in neurodevelopmental disorders</article-title>
<source/>Am J Human Genet
          <year>2014</year>
<volume>94</volume>
<fpage>415</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2014.02.001</pub-id>
<pub-id pub-id-type="pmid">24581740</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polyak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>An assessment of sex bias in neurodevelopmental disorders</article-title>
<source/>Genome Med
          <year>2015</year>
<volume>7</volume>
<fpage>94</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-015-0216-5</pub-id>
<pub-id pub-id-type="pmid">26307204</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rees</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Chambert</surname>
<given-names>KD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CNV analysis in a large schizophrenia sample implicates deletions at 16p12. 1 and SLC1A1 and duplications at 1p36. 33 and CGNL1</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<fpage>1669</fpage>
<lpage>1676</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt540</pub-id>
<pub-id pub-id-type="pmid">24163246</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CNVs conferring risk of autism or schizophrenia affect cognition in controls</article-title>
<source/>Nature
          <year>2014</year>
<volume>505</volume>
<fpage>361</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1038/nature12818</pub-id>
<pub-id pub-id-type="pmid">24352232</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreno-De-Luca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Boomer</surname>
<given-names>KB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of parental cognitive, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions</article-title>
<source/>JAMA Psychiatry
          <year>2015</year>
<volume>72</volume>
<fpage>119</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2147</pub-id>
<pub-id pub-id-type="pmid">25493922</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaassen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Duijff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Swanenburg de Veye</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Explaining the variable penetrance of CNVs: parental intelligence modulates expression of intellectual impairment caused by the 22q11.2 deletion</article-title>
<source/>Am J Med Genet B
          <year>2016</year>
<volume>171</volume>
<fpage>790</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32441</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simons Vip</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Simons Variation in Individuals Project (Simons VIP): a genetics-first approach to studying autism spectrum and related neurodevelopmental disorders</article-title>
<source/>Neuron
          <year>2012</year>
<volume>73</volume>
<fpage>1063</fpage>
<lpage>1067</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.02.014</pub-id>
<pub-id pub-id-type="pmid">22445335</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerrini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cellini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variable epilepsy phenotypes associated with a familial intragenic deletion of the SCN1A gene</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<fpage>2474</fpage>
<lpage>2477</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02790.x</pub-id>
<pub-id pub-id-type="pmid">21204810</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Low load for disruptive mutations in autism genes and their biased transmission</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2015</year>
<volume>112</volume>
<fpage>E5600</fpage>
<lpage>5607</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1516376112</pub-id>
<pub-id pub-id-type="pmid">26401017</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karczewski</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Minikel</surname>
<given-names>EV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>
<source/>Nature
          <year>2016</year>
<volume>536</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1038/nature19057</pub-id>
<pub-id pub-id-type="pmid">27535533</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goh</surname>
<given-names>KI</given-names>
</name>
<name>
<surname>Cusick</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Childs</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Vidal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barabási</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>The human disease network</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2007</year>
<volume>104</volume>
<fpage>8685</fpage>
<lpage>8690</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0701361104</pub-id>
<pub-id pub-id-type="pmid">17502601</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>JTR</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability</article-title>
<source/>Nat Genet
          <year>2017</year>
<volume>49</volume>
<fpage>1167</fpage>
<lpage>1173</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3903</pub-id>
<pub-id pub-id-type="pmid">28650482</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Dickel</surname>
<given-names>DE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomic patterns of de novo mutation in simplex autism</article-title>
<source/>Cell
          <year>2017</year>
<volume>171</volume>
<fpage>710</fpage>
<lpage>22 e712</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.08.047</pub-id>
<pub-id pub-id-type="pmid">28965761</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandler</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Antaki</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gujral</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Paternally inherited cis-regulatory structural variants are associated with autism</article-title>
<source/>Science
          <year>2018</year>
<volume>360</volume>
<fpage>327</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1126/science.aan2261</pub-id>
<pub-id pub-id-type="pmid">29674594</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Histone modifier genes alter conotruncal heart phenotypes in 22q11.2 deletion syndrome</article-title>
<source/>Am J Hum Genet
          <year>2015</year>
<volume>97</volume>
<fpage>869</fpage>
<lpage>877</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.10.013</pub-id>
<pub-id pub-id-type="pmid">26608785</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grillo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Bianciardi</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Revealing the complexity of a monogenic disease: Rett syndrome exome sequencing</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e56599</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0056599</pub-id>
<pub-id pub-id-type="pmid">23468869</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuurs-Hoeijmakers</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Vissers</surname>
<given-names>LE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome</article-title>
<source/>Am J Hum Genet
          <year>2012</year>
<volume>91</volume>
<fpage>1122</fpage>
<lpage>1127</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2012.10.013</pub-id>
<pub-id pub-id-type="pmid">23159249</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>